Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl- (4-chlorophenyl) - (3-trifluoromethylphenoxy) -acetate (halofenate) , a derivative of clofibrate
Keller, C.; Wolfram, G.; Zöllner, N.
Arzneimittel-Forschung 26(12): 2221-2224
1976
ISSN/ISBN: 0004-4172 PMID: 798591 Document Number: 100687
23 patients with hyperlipidemia and hyperuricemia received acetamidoethyl-(4-chlorophenyl)-(trifluoromethylphenoxy)-acetate (halofenate), a clofibrate derivative, and probenecid or probenecid and placebo over 36 weeks following a placebo period of 6 weeks. Halofenate compared with probenecid lowered elevated serum uric acid levels satisfactorily to a therapeutic level between 5 and 6 mg/100 ml. Serum triglyceride levels were not always lowered sufficiently, serum cholesterol levels were not influenced.